Delivery Order SPE2DB22D1017-SPE2DB25FG7GT
- Not listed
- The Defense Logistics Agency (DLA) awarded a $10,948.05 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency awarded a $4,030.74 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitively awarded contract employs firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $1,311.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on September 5, 2025, with completion scheduled for September 8, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $35,436.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a single line item fulfilling pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,574.60 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on April 21, 2025, with an ultimate completion date of April 22, 2025. This non-set-aside contract utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999.99 billion and extends...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $19,464.52 to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Otezla 30 mg tablets (60 count). This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, with an ultimate completion date of September 30, 2025. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7GTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,036.40 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed price delivery order issued under a non-set-aside, competitively awarded procurement vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through its extensive portfolio of pharmaceutical products and medical supplies for military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and the U.S. Coast Guard. The contract reflects the DLA's broader strategy to maintain flexible pharmaceutical supply chains capable of supporting the full spectrum of military medical needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/14/25 |